The American Academy Of Pain Medicine

The physicians' voice in pain medicine
  • Foundation
  • Store
  • Career Center
  • Press
  • Join-Renew
Search: Go
Member Login: Login

Enter the AAPM
Members' Community

  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Safe Prescribing Resources
  • PI-CME Portal

Library

Home > Library > For Pain Researchers > 2012 Poster Abstracts
  • Research in the News
  • For Pain Researchers
    • 2013 Poster Abstracts
    • 2012 Poster Abstracts
    • Research Resources
    • Research Presentations
    • Search Clinical Trials (NIH)
    • Register a Clinical Trial (NIH)
    • Medline - US National Library of Medicine
  • Clinical Guidelines and Resources
  • Pain Facts
  • Archives
  • FDA Updates, Recalls and Warnings
  • Presented at the 2012 AAPM Annual Meeting « Back

    282A

    Comparison of Morning and Evening Dosing of Extended-Release Hydromorphone on Sleep-Disordered Breathing in Patients with Low Back Pain

    Lynn Webster, MD lwebstermd@gmail1, Matt Iverson, MPH1, Mike Smith1, Jane Steffens2, (1) Lifetree Clinical Research, Salt Lake City, UT, (2) Covidien, St. Louis, MO

    View Poster

    Introduction: Chronic opioid exposure has been associated with sleep-disordered breathing.1,2 We studied the effect of dosing time (AM or PM) of 24-hour ER hydromorphone on sleep physiology in low back pain patients. Materials and Methods: An Institutional Review Board approved the protocol. Following an open-label immediate-release hydromorphone titration phase, the subjects were randomized in a placebo-controlled, double-blind phase of AM or PM dosing of ER hydromorphone. Fifteen patients were stabilized on ER hydromorphone 8 mg (n=10), 12 mg (n=2), or 16 mg (n=3) administered once-daily either AM or PM for at least 14 days and then crossed over to the alternate dosing regimen. Overnight sleep studies were performed at baseline, following IR hydromorphone titration, and following each ER hydromorphone dosing period. Results: AM dosing appeared to produce fewer night-time respiratory events than PM dosing as demonstrated by lower mean Apnea-Hypopnea Index (AHI) scores (12.9 v 17.1, p=0.1248). Apnea episodes were also less frequent with AM dosing than PM dosing (52.9 v 62.3 events, p=0.0829). The number of oxygen desaturation events with AM dosing was less than half than with PM dosing (33.8 v 71.6 events, p=0.0870) as was the amount of time oxygen saturation was below 88% (17.7 v 40.8 minutes, p=0.2707). Pain control and most other sleep measures were comparable between the groups. Conclusions: Morning dosing of ER hydromorphone appeared to be associated with fewer respiratory events than evening dosing. References: 1)Farney RJ, Walker JM, Cloward TV, Rhondeau S. Sleep-disordered breathing associated with long-term opioid therapy. Chest 2003;123:632-9. 2)Webster LR, Choi Y, Desai H, Webster L, Grant JB. Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008;9:425-32.

    Funding: None

  • Home
  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Contact Us
  • Members' Community
  • Privacy Policy
  • Sitemap
Close

Members Only Alert Message

Please login to access AAPM member only information.
Forgot your login information?

Sign Up Today!

Join AAPM today and be part of the primary organization for physicians practicing in the specialty of pain medicine and begin accessing AAPM member benefits. 

Join
Or

Log In

Please log in and you will be redirected to the requested page.

Log In